WallStreetZenWallStreetZen

NASDAQ: TNXP
Tonix Pharmaceuticals Holding Corp Stock

$0.37+0.00 (+0%)
Updated Feb 28, 2024
TNXP Price
$0.37
Fair Value Price
N/A
Market Cap
$8.92M
52 Week Low
$0.26
52 Week High
$4.94
P/E
-0.04x
P/B
0.07x
P/S
2.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.99M
Earnings
-$121.02M
Gross Margin
40.5%
Operating Margin
-3,033.74%
Profit Margin
-3,094%
Debt to Equity
0.15
Operating Cash Flow
-$102M
Beta
0.62
Next Earnings
Mar 11, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TNXP Overview

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TNXP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TNXP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TNXP is good value based on its book value relative to its share price (0.07x), compared to the US Biotechnology industry average (6.14x)
P/B vs Industry Valuation
TNXP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TNXP due diligence checks available for Premium users.

Be the first to know about important TNXP news, forecast changes, insider trades & much more!

TNXP News

Valuation

TNXP fair value

Fair Value of TNXP stock based on Discounted Cash Flow (DCF)
Price
$0.37
Fair Value
$1.42
Undervalued by
73.91%
TNXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TNXP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.04x
Industry
13.96x
Market
35.52x

TNXP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.07x
Industry
6.14x
TNXP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TNXP's financial health

Profit margin

Revenue
$4.0M
Net Income
-$28.0M
Profit Margin
-701.3%
TNXP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TNXP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$139.3M
Liabilities
$18.4M
Debt to equity
0.15
TNXP's short-term assets ($31.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNXP's short-term assets ($31.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNXP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TNXP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.4M
Investing
-$821.0k
Financing
$6.3M
TNXP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TNXP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TNXP$8.92M+1.63%-0.04x0.07x
PHXM$9.00M-8.33%-0.73x0.23x
ABVC$8.79M-1.22%-0.34x0.97x
CVKD$8.78M+11.96%-0.53x1.00x
AEZS$9.08M-2.09%-0.39x0.35x

Tonix Pharmaceuticals Holding Stock FAQ

What is Tonix Pharmaceuticals Holding's quote symbol?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding trades on the NASDAQ under the ticker symbol TNXP. Tonix Pharmaceuticals Holding stock quotes can also be displayed as NASDAQ: TNXP.

If you're new to stock investing, here's how to buy Tonix Pharmaceuticals Holding stock.

What is the 52 week high and low for Tonix Pharmaceuticals Holding (NASDAQ: TNXP)?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's 52-week high was $4.94, and its 52-week low was $0.26. It is currently -92.42% from its 52-week high and 43.85% from its 52-week low.

How much is Tonix Pharmaceuticals Holding stock worth today?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding currently has 23,849,341 outstanding shares. With Tonix Pharmaceuticals Holding stock trading at $0.37 per share, the total value of Tonix Pharmaceuticals Holding stock (market capitalization) is $8.92M.

Tonix Pharmaceuticals Holding stock was originally listed at a price of $30,000.00 in May 10, 2012. If you had invested in Tonix Pharmaceuticals Holding stock at $30,000.00, your return over the last 11 years would have been -100%, for an annualized return of -64.18% (not including any dividends or dividend reinvestments).

How much is Tonix Pharmaceuticals Holding's stock price per share?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding stock price per share is $0.37 today (as of Feb 28, 2024).

What is Tonix Pharmaceuticals Holding's Market Cap?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's market cap is $8.92M, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tonix Pharmaceuticals Holding's market cap is calculated by multiplying TNXP's current stock price of $0.37 by TNXP's total outstanding shares of 23,849,341.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.